Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2017

View Archived Issues

EMA grants SPK-9001 access to PRIME program for hemophilia B

Melinta and Menarini sign development and commercialization agreement for delafloxacin

EMA grants orphan drug designation to Resolaris for limb girdle muscular dystrophy

Theratechnologies acquires commercial rights to ibalizumab in E.U. and other countries

C5aR1 as a potential new therapeutic target in Gaucher disease

FDA approves Noctiva for nocturnal polyuria

Chemotherapy-induced pyrimidine synthesis provides a target for triple-negative breast cancer

Santen Pharmaceutical and Singapore Eye Research Institute launch 5-year ophthalmic collaboration

PRC2 and BET bromodomain proteins as therapeutic targets for diffuse intrinsic pontine gliomas

Amryt completes phase III discussions with FDA and EMA for AP-101 in epidermolysis bullosa

Phase I study of Lymfactin advances to highest dose level

Cabozantinib S-malate from Exelixis granted U.S. orphan drug designation for the treatment of HCC

Vernalis and Servier establish new 2-year oncology drug discovery collaboration

TiGenix updates progress of European MAA procedure for Cx-601

Genetic analyses of phase II studies of Qbeco in Crohn's disease and ulcerative colitis

FORUM Pharmaceuticals discloses novel CHRNA7 agonists

Incyte identifies new TAM kinase inhibitors

U.S. Dept. of Health & Human Services patents thioredoxin reductase inhibitors

Memorial Sloan-Kettering presents novel Mcl-1 inhibitors

Zafgen discovers methionine aminopeptidase 2 inhibitors

The Broad Institute patents anti-mycobacterial compounds

Angsana to provide Asian diagnostic screening for STARTRK-2 trial of entrectinib

Phase I results presented for ANB-020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...